SANOVO
What it tests: Savolitinib vs placebo added to osimertinib in treatment-naïve EGFR-mutant NSCLC with MET overexpression
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.